Noxxon to initiate phase Ib clinical trial of MCP-1 inhibitor NOX-E36
The double-blind, placebo controlled, Phase I study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the MCP-1 inhibitor NOX-E36 in four groups of subjects. The first group, composed of healthy volunteers, will receive NOX-E36 i.v. every other day for 15 days. The three remaining groups, composed of type II diabetic patients, will receive ascending doses of NOX-E36 i.v. every other day for 27 days.
Dr Frank Morich, CEO of NOXXON Pharma AG, commented: " The pharmacokinetic and pharmacodynamic data from diabetic patients who will be enrolled in this NOX-E36 study will guide NOXXON in choosing the doses and endpoints most likely to reveal the therapeutic potential of NOX-E36 in a Phase II program. Given the absence of existing therapies in the indications targeted by NOX-E36 the inclusion of diabetic patients is a crucial step in defining the best path forward."
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.